Navigation Links
CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved
Date:10/10/2008

CORPUS CHRISTI, Texas, Oct. 10 /PRNewswire-FirstCall/ -- CSMG Technologies, Inc., (OTC Bulletin Board: CTGI), a technology management company, announced the company has received approval of its fifth U.S. patent. The approval is on a key divisional application for "Bonding of Soft Biological Tissues by Passing High Frequency Electric Current Therethrough" for CSMG Technologies subsidiary Live Tissue Connects ("LTC") platform tissue bonding/welding technology. The patent approval follows the issuance of four other U.S. patents, a European Union patent, in eight European countries, Ukraine, Canada and Australia with 14 U.S. and international patents pending.

Donald S. Robbins, President and CEO of CSMG Technologies, said, "This key U.S. patent approval re-enforces our patent portfolio and expands LTC's commercial possibilities while increasing our shareholder value. Our strong patent portfolio, and a disruptive technology as well as ISO 13485:2003 certification for the design and manufacture of Bipolar Forceps Systems, recent US FDA 510(k) clearance and European Union C. E. Mark certification on LTC's VAD.400 electrosurgery generator and two instruments puts us in an excellent position of competing in global medical device markets."

"Our LTC team has presented comparative results at conferences with the LTC bipolar sealing system and shown that LTC's bipolar sealing system has broad applications. Additionally, in preparation for launching LTC's commercial product I early 2009, LTC has begun building inventory for both LTC's electro surgery generator and hand instrument for duct and vessel sealing, and are in discussions with interested international medical device companies and distributors," Mr. Robbins added.

About Live Tissue Connect

LTC's surgical tissue bonding / welding device is a patented platform technology that bonds and reconnects human soft tissue through fusion, in contrast with conventional wound closing devices such as sutures, staples, sealant, or glues. LTC currently holds a total of approximately 31 patents and pending patents in the U.S., Australia, Canada, European Union, Ukraine and other countries.

For further information on Live Tissue Connect, please visit the LTC website at http://www.livetissueconnect.com.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at http://www.csmgtechinternational.com.

Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to: http://www.csmgtechinternational.com/contact_information.html and fill-in information.

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.


'/>"/>
SOURCE CSMG Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
2. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
5. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
6. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
7. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
8. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
9. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
10. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
11. DNA Sequencing Equipment Market to Fragment and Grow as Competition, New Technologies Develop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):